Company Overview
Snapshot
Founded in January 2020 by David Risin and Dr. Ayelet Ben Barak, LIBI-Diagnostics operates with 1–10 employees. The company has secured funding across one round from one investor, with a notable investment from Headstart.
Business overview
LIBI-Diagnostics is a Health Tech & Life Sciences startup specializing in cancer diagnostics. The company develops gene-biomarker tests for the early detection of cancer, utilizing next-generation bio-liquid tests. Their core technology involves state-of-the-art Next-Generation Sequencing (NGS) to customize tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples, compared to genomic expression data in primary tumors. LIBI-Diagnostics aims to provide a practical solution to the inefficiencies of periodic imaging tests, enabling early diagnosis of recurrent cancerous development with minimal cells, thereby potentially sparing patients aggressive treatments. The company primarily serves the healthcare and patient markets, operating within the Pharma & Medical Biotechnology sector, specifically in Test Diagnostics & Screening.
Log in to access full profile ›Company Intelligence Q&A
- What is LIBI-Diagnostics' primary focus?
- LIBI-Diagnostics focuses on the early detection of cancer through gene-biomarker tests, utilizing next-generation bio-liquid tests and Next-Generation Sequencing (NGS) technology.
- When was LIBI-Diagnostics founded?
- LIBI-Diagnostics was founded in January 2020.
- Who are the founders of LIBI-Diagnostics?
- The company was founded by David Risin and Dr. Ayelet Ben Barak.
- What technology does LIBI-Diagnostics use for its diagnostic tests?
- LIBI-Diagnostics uses state-of-the-art Next-Generation Sequencing (NGS) technology to detect alterations of Aurora Kinase A in patient samples.